Gene
CCNE1
CCNE1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (25), Actionable biomarkers (1), Trial mentions (31), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CCNE1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 6 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 2 of 8,738 | 0.02% | not measured | |
| 2025 | 5 of 8,875 | 0.06% | not measured | |
| 2024 | 4 of 8,597 | 0.05% | not measured | |
| 2023 | 4 of 8,275 | 0.05% | 23 of 11,460 | 0.20% |
| 2022 | 3 of 8,285 | 0.04% | 18 of 13,598 | 0.13% |
| 2021 | 2 of 8,692 | 0.02% | 30 of 15,045 | 0.20% |
| 2020 | 2 of 7,640 | 0.03% | 20 of 14,459 | 0.14% |
| 2019 | 2 of 7,300 | 0.03% | 23 of 12,159 | 0.19% |
| 2018 | 0 of 6,927 | 0.00% | 17 of 11,854 | 0.14% |
| 2017 | 1 of 6,558 | 0.02% | 14 of 11,595 | 0.12% |
Showing 10 of 37 years.
Assay-provider ledger (25)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Cell Signaling Technology | Reagent supplier | Clinical validation | 1 | August 01, 2021 |
| DakoCytomation | Context dependent | Clinical validation | 1 | August 01, 2021 |
| Fitzgerald Industries International | Reagent supplier | Clinical validation | 1 | August 01, 2021 |
| Santa Cruz Biotechnology | Reagent supplier | Clinical validation | 2 | August 01, 2021 |
| Affymetrix | Reagent supplier | Clinical validationAnalytical validation | 2 | November 01, 2020 |
Showing 5 of 25 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CCNE1 amplification | Cdk2 Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (31)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT07288359 | Trial eligibility (AACT) |
| NCT04469764 | Trial eligibility (AACT) |
| NCT05773820 | Trial eligibility (AACT) |
| NCT05431582 | Trial eligibility (AACT) |
| NCT03718091 | Trial eligibility (AACT) |
Showing 5 of 31 trial mentions.
Target-disease associations (418)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| AIDS | genetic, familial or congenital disease | Literature (Europe PMC) |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Adult-onset autosomal recessive sideroblastic anemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alpha-thalassemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alpha-thalassemia - intellectual disability syndrome linked to chromosome 16 | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 418 associations.
Vendor sourcing (82)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Alliance for Clinical Trials in Oncology | Trial sponsor | Mentioned in trial textTrial free-text mention | CCNE1 | View trial NCT02523014 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1078A>G (p.I360V) alteration is located in exon 11 (coding exon 10) of the CCNE1 gene. This alteration results from a A to G substitution at nucleotide... | View ClinVar record SCV003543881.2 |
| Astrazeneca Plc | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | for all Modules: 1. Metastatic MIBC 2. 2nd/3rd line 3. Failed adjuvant/neo-adjuvant chemotherapy \<1 yr 4. 1 lesion ≥10 mm at baseline in the longest diamet... | View trial NCT02546661 |
| Astrazeneca Plc | Trial sponsor | Mentioned in trial textTrial free-text mention | CCNE1 | View trial NCT02546661 |
| Avenzo Therapeutics, Inc. | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | by study phase and part: i) Phase 1a Monotherapy Dose Escalation: Patients with locally advanced or metastatic HR+/HER2- breast cancer, CCNE1-amplified t... | View trial NCT05867251 |
Showing 5 of 82 sourcing records.
Trial-cited literature (214)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | 15 |
| Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2025 | 3 |
| Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21). | ESMO open | 2025 | 0 |
| Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. | The Journal of clinical investigation | 2024 | 47 |
| Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses. | JCO precision oncology | 2024 | 19 |
Showing 5 of 214 papers.
Literature-extracted relations (17)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Epirubicin | Chemical | positive_correlate |
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. | 2021 |
| BORTEZOMIB | Chemical | associate |
Synthetic lethality between CCNE1 amplification and loss of BRCA1. | 2013 |
| Platinum | Chemical | associate |
Synthetic lethality between CCNE1 amplification and loss of BRCA1. | 2013 |
| Triple Negative Breast Neoplasms | Disease | associate |
Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21). | 2025 |
| Neoplasms | Disease | associate |
Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer. | 2025 |
Showing 5 of 17 relation assertions.
Organizations publishing (287)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Dana-Farber Cancer Institute | Other | 21 | 2011 to 2025 |
| Memorial Sloan Kettering Cancer Center | Hospital | 19 | 2010 to 2025 |
| The University of Texas System | Academic | 15 | 2009 to 2023 |
| Government of the United States of America | Government | 12 | 2014 to 2024 |
| Harvard Medical School | Academic | 10 | 2015 to 2024 |
Showing 5 of 287 organizations.
Where CCNE1 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
375 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, protein variant mentions, and human sample screening reference.